IN2014KN00996A - - Google Patents

Info

Publication number
IN2014KN00996A
IN2014KN00996A IN996KON2014A IN2014KN00996A IN 2014KN00996 A IN2014KN00996 A IN 2014KN00996A IN 996KON2014 A IN996KON2014 A IN 996KON2014A IN 2014KN00996 A IN2014KN00996 A IN 2014KN00996A
Authority
IN
India
Prior art keywords
dexmedetomidine
administering
methods
subject matter
disclosed subject
Prior art date
Application number
Other languages
English (en)
Inventor
De Rocha Marcelo Garcia
Wayne Wisemandle
Dennis J Stalker
Edward Koo
Original Assignee
Hospira Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47226666&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014KN00996(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hospira Inc filed Critical Hospira Inc
Publication of IN2014KN00996A publication Critical patent/IN2014KN00996A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN996KON2014 2011-10-14 2012-09-27 IN2014KN00996A (uk)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161547626P 2011-10-14 2011-10-14
US13/343,693 US20130096170A1 (en) 2011-10-14 2012-01-04 Methods of treating pediatric patients using dexmedetomidine
US13/471,403 US8324260B1 (en) 2011-10-14 2012-05-14 Methods of treating pediatric patients using dexmedetomidine
PCT/US2012/057652 WO2013055528A1 (en) 2011-10-14 2012-09-27 Methods of treating pediatric patients using dexmedetomidine

Publications (1)

Publication Number Publication Date
IN2014KN00996A true IN2014KN00996A (uk) 2015-09-04

Family

ID=47226666

Family Applications (1)

Application Number Title Priority Date Filing Date
IN996KON2014 IN2014KN00996A (uk) 2011-10-14 2012-09-27

Country Status (23)

Country Link
US (8) US20130096170A1 (uk)
EP (2) EP3446691A1 (uk)
JP (5) JP6270727B2 (uk)
KR (3) KR20140094539A (uk)
CN (2) CN103957906A (uk)
AU (3) AU2012321246C1 (uk)
BR (1) BR112014008983A2 (uk)
CA (2) CA2851780C (uk)
CY (1) CY1121041T1 (uk)
DK (1) DK2766014T3 (uk)
ES (1) ES2685814T3 (uk)
HK (1) HK1200333A1 (uk)
HR (1) HRP20181378T1 (uk)
HU (1) HUE039671T2 (uk)
IL (2) IL232070A0 (uk)
IN (1) IN2014KN00996A (uk)
LT (1) LT2766014T (uk)
MX (1) MX362626B (uk)
PL (1) PL2766014T3 (uk)
PT (1) PT2766014T (uk)
RS (1) RS57660B1 (uk)
SI (1) SI2766014T1 (uk)
WO (1) WO2013055528A1 (uk)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130096170A1 (en) * 2011-10-14 2013-04-18 Hospira, Inc. Methods of treating pediatric patients using dexmedetomidine
US8242158B1 (en) 2012-01-04 2012-08-14 Hospira, Inc. Dexmedetomidine premix formulation
US20150098997A1 (en) 2013-10-07 2015-04-09 Teikoku Pharma Usa, Inc. Methods and Compositions for Treating Attention Deficit Hyperactivity Disorder, Anxiety and Insomnia Using Dexmedetomidine Transdermal Compositions
KR101891185B1 (ko) 2013-10-07 2018-08-24 테이코쿠 팔마 유에스에이, 인코포레이티드 비진정량의 덱스메데토미딘의 경피 전달을 위한 방법 및 조성물
CA2924188C (en) * 2013-10-07 2018-12-18 Teikoku Pharma Usa, Inc. Methods and compositions for managing pain comprising dexmedetomidine transdermal compositions
RU2018105761A (ru) 2013-10-07 2019-02-26 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. Устройства для трансдермальной доставки дексмедетомидина и способы их применения
US11017330B2 (en) * 2014-05-20 2021-05-25 Elasticsearch B.V. Method and system for analysing data
EP3182893B1 (en) * 2014-08-18 2024-02-07 Electronic Pain Assessment Technologies (EPAT) Pty Ltd A pain assessment system
CN104784174A (zh) * 2015-03-06 2015-07-22 北京大学第一医院 右美托咪定的药物新用途
US9717796B1 (en) * 2016-04-20 2017-08-01 Slypharma, Llc Heat sterilizeable, premixed, ready to use dexmedetomidine solution packaged in a flexible plastic container
BR112019006955A2 (pt) * 2016-10-31 2019-07-02 Teikoku Pharma Usa Inc métodos de controle da dor usando dispositivos de distribuição transdérmica de dexmedetomidina
CN106539778A (zh) * 2016-12-08 2017-03-29 武汉大学 一种小儿麻醉术前含服口腔泡腾片及其制备方法
BR112019013503A2 (pt) 2016-12-31 2020-01-07 Bioxcel Therapeutics, Inc. Uso de dexmedetomidina sublingual para o tratamento da agitação
US11783046B2 (en) 2017-04-26 2023-10-10 Elasticsearch B.V. Anomaly and causation detection in computing environments
US11621969B2 (en) 2017-04-26 2023-04-04 Elasticsearch B.V. Clustering and outlier detection in anomaly and causation detection for computing environments
CN108042533B (zh) * 2017-12-25 2020-11-13 苏州格兰科医药科技有限公司 右美托米定在制备用于预防和/或抑制创伤性脑损伤后的神经元死亡的药物组合物中的用途
WO2020006119A1 (en) * 2018-06-27 2020-01-02 Bioxcel Therapeutics, Inc. Methods for treating agitation using dexmedetomidine hydrochloride
CN114983981A (zh) 2018-06-27 2022-09-02 比奥克斯塞尔医疗股份有限公司 含右美托咪定的膜制剂及其制造方法
JP2022500407A (ja) * 2018-09-12 2022-01-04 ハフ イアー インスティテュート 人工内耳手術に伴う難聴の治療方法
US20220054455A1 (en) * 2018-09-13 2022-02-24 Taiwan Liposome Co., Ltd. Sustained-release pharmaceutical compositions comprising of a sedative drug and uses thereof
CA3123033A1 (en) * 2018-12-13 2020-06-18 Dignity Health System and method for detection and monitoring of over sedation to prevent harm to patients
US10817669B2 (en) 2019-01-14 2020-10-27 International Business Machines Corporation Automatic classification of adverse event text fragments
CN109793709A (zh) * 2019-02-22 2019-05-24 青岛农业大学 一种斑海豹用复方注射剂及其制备方法
US11000488B2 (en) * 2019-03-22 2021-05-11 Syntrix Biosystems Inc. Treating pain using desmetramadol
CA3145388A1 (en) 2019-07-19 2021-01-28 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
WO2021211507A1 (en) * 2020-04-17 2021-10-21 Bioventures, Llc Methods and systems for predicting the effect of inhaled and infused anesthetics
KR20230094816A (ko) 2021-12-21 2023-06-28 충남대학교산학협력단 감염 환자에서 반코마이신 최적 용량을 결정하는 방법
EP4386768A1 (en) * 2022-12-13 2024-06-19 Koninklijke Philips N.V. Active sleep apnea case finding and scheduling system and method of operation thereof
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4407957A (en) 1981-03-13 1983-10-04 Damon Corporation Reversible microencapsulation of a core material
JPS6058890A (ja) 1983-09-13 1985-04-05 Mizusawa Ind Chem Ltd 感熱記録紙用填剤
FI844786A0 (fi) 1984-12-04 1984-12-04 Farmos Oy Terapeutiskt utnyttjbar foerening.
GB2206880B (en) 1987-07-16 1991-04-24 Farmos Oy Optical isomers of an imidazole derivative
US5344840A (en) 1988-02-29 1994-09-06 Orion-Yhtyma Oy 4-substituted imidazole derivatives useful in perioperative care
US5217718A (en) 1989-08-18 1993-06-08 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
US5124157A (en) 1989-08-18 1992-06-23 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
FI894911A0 (fi) 1989-10-17 1989-10-17 Farmos Oy En terapeutiskt vaerdefull foerening.
US5304569A (en) 1989-11-13 1994-04-19 Orion-Yhtyma Oy Compositions and their use in lowering intraocular pressure
CA2109085C (en) 1991-04-25 2003-03-11 Keith E. Dionne Implantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic products
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
BR9307141A (pt) 1992-09-29 1999-03-30 Inhale Therapeutic Syst Processo para a liberação sistência pulsátil de um fragmento ativo de hormônio de paratiróide (PTH) para um hospedeiro mamífero e para um paciente e composição farmacêutica
GB2281206A (en) 1993-08-25 1995-03-01 Orion Yhtymae Oy Use of dexmedetomidine
FR2718357B1 (fr) 1994-04-06 1997-10-03 Defarges Alain Moreau Perfectionnements apportés à un dispositif d'injection par jet sans aiguille.
DE69519300T2 (de) 1994-08-08 2001-05-31 Debiopharm Sa Stabiles arzneimittel enthaltend oxaliplatin
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US5780014A (en) 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US5654007A (en) 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
DE19758564A1 (de) 1997-11-11 1999-08-26 Gruenenthal Gmbh Formulierung einer Kombination aus Morphin und einem alpha¶2¶-adrenergem Agonisten und deren Verwendung
US6716867B1 (en) * 1998-04-01 2004-04-06 Orion Corporation Use of dexmedetomidine for ICU sedation
AR015744A1 (es) * 1998-04-01 2001-05-16 Orion Corp Uso de dexmedetomidina para sedacion en terapia intensiva
PE20001396A1 (es) 1999-01-18 2000-12-23 Gruenenthal Chemie Formulaciones medicamentosas retardadas que contienen una combinacion de un opioide o una sal fisiologicamente tolerables del mismo, un o-agonista
GB9913677D0 (en) 1999-06-11 1999-08-11 Imperial College Formulation
US6806291B1 (en) 2003-10-09 2004-10-19 The Foundation For The Lsu Health Sciences Center Analgesic compounds, their synthesis and pharmaceutical compositions containing them
US20080308444A1 (en) 2007-06-13 2008-12-18 Baxter International Inc. Packaging system and method of alerting a practitioner
US20100197694A1 (en) 2008-08-01 2010-08-05 Gerald Horn Compositions and methods for treatment of diseases and conditions with increased vascular permeability
EP2165706A1 (en) 2008-09-18 2010-03-24 BioAlliance Pharma Treating Inflammatory Pain in Mucosa of the Oral Cavity Using Mucosal Prolonged Release Bioadhesive Therapeutic Carriers.
US7896843B2 (en) * 2008-10-15 2011-03-01 Bioquiddity, Inc. Special purpose fluid dispenser
US8100890B2 (en) 2008-10-15 2012-01-24 Bioquiddity, Inc. Special purpose fluid dispenser with pre-filled reservoir
JP5536661B2 (ja) 2008-10-30 2014-07-02 国立大学法人 岡山大学 局所麻酔用組成物
PE20120713A1 (es) 2009-05-15 2012-07-08 Recro Pharma Inc Composiciones sublinguales de dexmedetomidina y metodos para su uso
US8410140B2 (en) 2009-06-01 2013-04-02 The Regents Of The University Of Michigan Anesthetic methods and compositions
CA2782872A1 (en) 2009-12-17 2011-06-23 Alpha Synergy Development, Inc. Compositions and methods for ophthalmic delivery of nasal decongestants
FR2959414B1 (fr) 2010-04-30 2016-01-08 Luc Quintin Combinaison de molecules aux fins de traitement d'hypotension survenant au cours du choc septique, cardiogenique, ou anaphylactique refractaire, ou hemorragique terminal, apres correction de la volemie et de l'etat de mal asthmatique refractaire
US20130096170A1 (en) 2011-10-14 2013-04-18 Hospira, Inc. Methods of treating pediatric patients using dexmedetomidine
US8242158B1 (en) 2012-01-04 2012-08-14 Hospira, Inc. Dexmedetomidine premix formulation

Also Published As

Publication number Publication date
HK1200333A1 (en) 2015-08-07
US20130096170A1 (en) 2013-04-18
JP2022008828A (ja) 2022-01-14
IL232070A0 (en) 2014-05-28
JP2020073529A (ja) 2020-05-14
RS57660B1 (sr) 2018-11-30
EP2766014A1 (en) 2014-08-20
PL2766014T3 (pl) 2019-02-28
PT2766014T (pt) 2018-10-11
AU2012321246A1 (en) 2014-05-01
DK2766014T3 (en) 2018-09-24
LT2766014T (lt) 2018-08-27
AU2017206211A1 (en) 2017-08-03
SI2766014T1 (sl) 2018-11-30
EP2766014A4 (en) 2015-06-24
US20140005243A1 (en) 2014-01-02
AU2019203564A1 (en) 2019-06-13
US9314449B2 (en) 2016-04-19
JP6270727B2 (ja) 2018-01-31
CA2978258A1 (en) 2013-04-18
KR20200019791A (ko) 2020-02-24
JP6640164B2 (ja) 2020-02-05
HRP20181378T1 (hr) 2018-10-19
US20130096171A1 (en) 2013-04-18
JP2023179764A (ja) 2023-12-19
MX362626B (es) 2019-01-28
US20190269657A1 (en) 2019-09-05
JP2014528474A (ja) 2014-10-27
IL249991A0 (en) 2017-03-30
CA2851780C (en) 2017-11-28
CN103957906A (zh) 2014-07-30
BR112014008983A2 (pt) 2017-05-02
ES2685814T3 (es) 2018-10-11
US8507542B2 (en) 2013-08-13
JP2018027971A (ja) 2018-02-22
KR20140094539A (ko) 2014-07-30
EP2766014B1 (en) 2018-07-18
WO2013055528A1 (en) 2013-04-18
MX2014004548A (es) 2015-02-12
US8324260B1 (en) 2012-12-04
AU2017206211B2 (en) 2019-02-28
CY1121041T1 (el) 2019-12-11
AU2012321246C1 (en) 2017-11-02
CA2851780A1 (en) 2013-04-18
US20160067220A1 (en) 2016-03-10
CN109700806A (zh) 2019-05-03
US20210137891A1 (en) 2021-05-13
US20130096172A1 (en) 2013-04-18
AU2012321246B2 (en) 2017-05-04
HUE039671T2 (hu) 2019-01-28
KR20190029775A (ko) 2019-03-20
EP3446691A1 (en) 2019-02-27

Similar Documents

Publication Publication Date Title
IN2014KN00996A (uk)
UA115139C2 (uk) Спосіб доставки фармацевтичної композиції, яка містить омепразол й ацетилсаліцилову кислоту, пацієнту
NZ732507A (en) Improved compositions for treating muscular dystrophy
WO2012023623A3 (ja) ハンター症候群の治療剤
MY173215A (en) Acetylcysteine compositions and methods of use thereof
EP3904502A3 (en) Compositions and methods
GB2491328A (en) Immediate/delayed drug delivery
GB2491327A (en) Delayed prolonged drug delivery
MY159353A (en) Pirfenidone treatment for patients with atypical liver function
MX2011007589A (es) Tratamiento de un cancer usando una combinacion de bendamustine y un anticuerpo anti-cd20.
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
EP2726066A4 (en) DOSAGE FORMS FOR ORAL ADMINISTRATION AND METHODS OF TREATMENT USING THE SAME
NZ714963A (en) Compositions and methods for treating anemia
EP2702994A3 (en) Methods of administering pirfenidone therapy
GB201111485D0 (en) Drug composition and its use in therapy
CL2014002935A1 (es) Metodo para tratar un paciente humano con esclerosis multiple con laquinimod, en una dosis diaria de alrededor de 1,2mg; un aforma de dosificacion unitaria oral de 1,2 mg de laquinimod y un portador
MX350666B (es) Composiciones y sus usos para tratar hiperuricemia y trastornos metabolicos asociados con hiperuricemia.
UA105191C2 (uk) Лікування пірфенідоном пацієнтів з атиповою функцією печінки
MX2013006319A (es) Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k y un inhibidor de mek.
MX348418B (es) Composicion ocular que contiene bromfenaco con biodisponibilidad incrementada.
WO2014071168A3 (en) Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients
GB201022049D0 (en) Methods
MX348723B (es) Combinaciones de solifenacina y estimulantes salivales para el tratamiento de la vejiga hiperactiva.
TN2014000418A1 (en) Methods for treating cancer using pi3k inhibitor and mek inhibitor
MX337593B (es) Gemcabeno y derivados para tratar la pancreatitis.